


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A composition of matter of the formula



and multimers thereof, wherein:

F^1 is an Fc domain;


X^1 and X^2 are each independently selected from $-(L^1)_c-P^1$, $-(L^1)_c-P^1-(L^2)_d-P^2$, $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3$, and $-(L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4$

P^1 , P^2 , P^3 , and P^4 are each independently randomized TPO-mimetic peptide sequences of pharmacologically active peptides;


L^1 , L^2 , L^3 , and L^4 are each independently linkers; and

a , b , c , d , e , and f are each independently 0 or 1, provided that at least one of a and b is 1 and wherein "peptide" refers to molecules 2 to 40 amino acid and wherein neither X^1 nor X^2 is a native protein.


2. (original) The composition of matter of Claim 1 of the formulae




or



3. (original) The composition of matter of Claim 1 of the formula



4. (original) The composition of matter of Claim 1 of the formula



5. (original) The composition of matter of Claim 1 wherein F^1 is an IgG Fc domain.

6. (original) The composition of matter of Claim 1 wherein F^1 is an IgG1 Fc domain.

7. (original) The composition of matter of Claim 1 wherein F^1 comprises the sequence of SEQ ID NO: 2.

Claims 8-18 (canceled).

19. (currently amended) The composition of matter of Claim [[18]]1 wherein P¹ is a TPO-mimetic peptide sequence selected from Table 16.
20. (currently amended) The composition of matter of Claim [[18]]1 wherein F¹ comprises the sequence of SEQ ID NO: 2.
21. (currently amended) The composition of matter of Claim [[18]]1 having a sequence selected from SEQ ID NOS: 6 and 12.

Claims 22 - 51 (canceled).